Chinese biopharma firm Antengene seeks Hong Kong listing
Antengene Corp, a clinical stage biopharmaceutical company, has set the ball rolling for a Hong Kong IPO, adding to a bulging pipeline of healthcare firms targeting the city’s bourse.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts